Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$0.54 - $0.8 $232 - $344
430 Added 355.37%
551 $0
Q2 2023

Aug 14, 2023

BUY
$0.45 - $0.81 $14 - $26
33 Added 37.5%
121 $0
Q1 2023

May 15, 2023

SELL
$0.45 - $0.87 $158 - $306
-352 Reduced 80.0%
88 $0
Q4 2022

Feb 14, 2023

BUY
$0.73 - $10.71 $264 - $3,887
363 Added 471.43%
440 $0
Q3 2022

Nov 14, 2022

SELL
$0.94 - $10.98 $787 - $9,201
-838 Reduced 91.58%
77 $0
Q2 2022

Aug 15, 2022

SELL
$1.16 - $1.97 $903 - $1,534
-779 Reduced 45.99%
915 $1,000
Q1 2022

May 16, 2022

BUY
$1.16 - $2.15 $1,324 - $2,455
1,142 Added 206.88%
1,694 $3,000
Q4 2021

Feb 14, 2022

BUY
$1.8 - $5.84 $993 - $3,223
552 New
552 $1,000

About XORTX Therapeutics Inc.


  • Ticker XRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,389,700
  • Market Cap $25.2M
  • Description
  • XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic ki...
More about XRTX
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.